Inozyme Pharma announced the grant of an inducement award outside of the Company’s 2020 Stock Incentive Plan to its newly appointed Chief Operations Officer, Matthew Winton, Ph.D. The inducement award was approved by the Board of Directors effective as of April 3, 2023, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as an inducement material to Dr. Winton entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grant is a nonstatutory option to purchase up to 250,000 shares of the Company’s common stock, at an exercise price of $5.39 per share, the closing price per share of the Company’s common stock as reported by Nasdaq on April 3, 2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on INZY:
- Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer
- Inozyme director Hopfner buys $1.6M in company shares
- Inozyme upgraded to Buy from Hold at Jefferies
- Inozyme expects cash to fund requirements into 4Q24
- Inozyme appoints Matthew Winton as COO
